BACE1 and Alzheimer disease: Six potential BACE1 drugs such as Atabecestat, Umibecestat, LY3202626, Elenbecestat, Lanabecestat, and Verubecestat, showed initial benefits in reducing the amyloid-beta plaques responsible for AD-related symptoms [18,19,20].